THERAGLIO
Microbubble driven multimodal imaging and theranostics for gliomas
| Coordinatore | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 10˙283˙796 € |
| EC contributo | 5˙998˙890 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
IT (MILANO) | coordinator | 1˙315˙728.00 |
| 2 |
THE FOUNDATION FOR MEDICAL RESEARCHINFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV
Organization address
address: WEIZMANN STREET 6 contact info |
IL (Tel Aviv) | participant | 1˙007˙354.00 |
| 3 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 864˙150.00 |
| 4 |
MEDCOM GESELLSCHAFT FUER MEDIZINISCHE BILDVERARBEITUNG MBH
Organization address
address: RUNDETURMSTRASSE 12 contact info |
DE (DARMSTADT) | participant | 630˙500.00 |
| 5 |
SEROSCIENCE KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Organization address
address: LORANT UTCA 10 B EP FSZT 2 contact info |
HU (BUDAPEST) | participant | 478˙900.00 |
| 6 |
PRAXIS BIOPHARMA RESEARCH INSTITUTE SL
Organization address
address: CALLE HERMANOS LUMIERE 5 contact info |
ES (Vitoria-Gasteiz) | participant | 474˙301.00 |
| 7 |
CAMELOT BIOMEDICAL SYSTEMS SRL
Organization address
address: VIA GRETO DI CORNIGLIANO 6R contact info |
IT (GENOVA) | participant | 452˙840.00 |
| 8 |
ESAOTE SPA
Organization address
address: VIALE BIANCA MARIA 25 contact info |
IT (MILANO) | participant | 368˙750.00 |
| 9 |
NANOMOL TECHNOLOGIES SA
Organization address
address: LG EDIFICI EUREKA.CAMPUS UAB BELLATERRA contact info |
ES (CERDANYOLA DEL VALLES) | participant | 280˙574.00 |
| 10 |
CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL
Organization address
address: Via Giuseppe Mussi 1 contact info |
IT (MILANO) | participant | 125˙793.00 |
| 11 |
MAGFORCE AG
Organization address
address: MAX-PLANCK-STRASSE 3 contact info |
DE (BERLIN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastomas, a rare cancer. Intraoperative Contrast-Enhanced US-imaging (CEUS) using lipidic MBs hold promises in increasing extent of resection of such tumors. Furthermore, MBs gained recently interest as a delivery system for drugs. We will develop a new generation of multimodal MBs, acting simultaneously as contrast agent for Magnetic Resonance Imaging (MRI), CEUS and intra-operative fluorescence for multimodal real-time image-guided resection of glioblastomas. We plan to transform MBs by replacing air with perfluorcarbon gas and/or attaching super-paramagnetic-iron-oxide nanoparticles for MRI visualization. We will also engineer MBs with RGD-motif to adhere selectively to pathological endothelial integrins and with near-infrared fluorophores for simultaneous US deep tissue imaging and direct microscopic tumour visualization to maximize resection. A software will be developed for integration of preoperative MRI, intraoperative US and microscopic imaging. We will focus on lipidic and polymeric MBs. Lipidic MBs are approved for clinical use; therefore, once modified, more easily translatable into clinical applications to reach a feasibility study on patients. In addition, we will improve multifunctional, polymer-based MBs. Multifunctional-stabilized-polymer-MBs are more stable and more versatile to be complexed with different molecules or nanoparticles as compared to lipidic Mbs and will be designed as a platform for delivering standard and/or experimental chemotherapeutic drugs to the tumour, acting as an innovative way for local targeting and delivering any kind of agent to a specific target, in a safe and controlled fashion. This would be a big step forward in the field of personalized medicine, moving standard MG image-guided treatment towards more effective, safer, molecular-based tailored interventions to specific patients.'